We’re proud to share that TaiMed Biologics’ world-first long-acting dual antibody HIV therapy, TMB-365/TMB-380, has been recognized with the 22nd National Innovation Award – Corporate Innovation Award (Biopharmaceuticals & Precision Medicine).

Accepted on behalf of TaiMed by our CEO, Dr. Chin-Ming Chang, this milestone underscores the innovation behind our long-acting dual bNAb platform—designed to maintain durable viral suppression with dosing just once every eight weeks, significantly improving patient convenience and quality of life.

TMB-365/TMB-380 has advanced into Phase 2b clinical trials in the U.S., and we anticipate that FDA Breakthrough Therapy Designation (BTD), if granted, will further accelerate development and regulatory review. With compelling Phase 2a data demonstrating sustained viral suppression, broad neutralization, and a strong safety profile, we believe this program represents a meaningful step forward in reshaping HIV treatment.

This achievement reflects not only national recognition, but also growing global momentum as we continue to advance clinical development, strategic partnerships, and our mission to deliver more convenient, next-generation HIV therapies to patients worldwide.